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GENERAL REMARKS 
1. Melting points (mp) were taken in open capillaries on Thomas 
Hoover melting point apparatus and are uncorrected.  
 
2. The Infrared spectra were recorded in film or in potassium 
bromide disks on a Bruker 398 spectrometer.  
 
3. The Proton Nuclear Magnetic Resonance spectra were 
recorded on a DPX-500 MHz Bruker FT-NMR spectrometer. 
The chemical shifts were reported as parts per million (δ ppm) 
using tetramethylsilane (TMS) as an internal standard.  
 
4. Mass spectra were obtained on a JEOL-SX-102 instrument 
using fast atom bombardment (FAB positive).  
 
5. Elemental analyses were performed on a Perkin-Elmer 2400 
C, H, and N analyzer.  
 
6. Conventional reflux reactions were carried out by using 
Scientific Microwave systems (CATALYST SYSTEMS).   
 
7. All reactions were monitored by thin layer chromatography on 
readymade silica gel plates (Merck).  
 
8. Iodine was used as a developing agent. Spectral data (IR, NMR 
and MASS) confirmed the structures of the synthesized 
compounds and the purity of these compounds was 
ascertained by microanalysis.  
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CHAPTER -1 
1. INTRODUCTION 
Chemistry is a very broad subject, and can justly claim to encompass many 
aspects of the study of biological molecules. To most researchers in the cancer 
fields,  the  term  ‘chemistry’  is  often  used  in  a  much  narrower  way  and  is 
synonymous with the synthetic chemistry as a tool for the discovery of anticancer 
drugs. 
1.1.  PHARMACEUTICAL CHEMISTRY 
  Pharmaceutical  Chemistry  is  an  area  of  chemistry  that  deals  with  the 
structure, properties and reaction of compounds that contains carbon. Chemists in 
general and organic chemists in particular can create new molecules never before 
proposed which, if carefully designed, may have important properties for the 
betterment of the human experience. One of the main objectives of organic and 
medicinal chemistry is the design, synthesis and production of molecule having 
value as human therapeutic agents1. The department of pharmaceutical chemistry is 
to impart in depth knowledge about all the chemical aspects of drugs and natural 
products, such as the structure, synthesis, isolation and structural activity 
relationship with the pharmacological activity. 
Medicinal chemistry  
   Medicinal chemistry and bioorganic chemistry is concerned with the 
design, synthesis and analysis of the relationship between molecular structure and  
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biological activity for compounds that can be used for the care or treatment of 
disease
1
. In medicinal chemistry, the chemist attempts to design and synthesis a 
medicine or pharmaceutical agent which will benefit humanity.  Such a compound 
could be called as a ‘drug’. 
Medicinal chemistry is a part of pharmaceutical chemistry. Medicinal 
chemistry is discipline at the intersection of chemistry and pharmacology involved 
with designing, synthesizing and developing pharmaceutical drugs. Medicinal 
chemistry involves the identification, synthesis and development of new chemical 
entities suitable for therapeutic use. It also includes the study of existing drugs, their 
biological properties and their quantitative structure activity relationship (QSAR). 
Medicinal chemistry is the application of chemical research techniques to the 
synthesis of pharmaceuticals. During the early stages of medicinal chemistry 
development, scientist were primarily concern with the isolation of the medicinal 
agents founds in plants. Today, scientists in this field are also equally concerned 
with creation of new synthetic drug compounds. Medicinal chemistry almost always 
geared towards drug discovery and development 
The first step is pharmaceutical focused on quality aspects of medicines and 
aims to assure fitness for the purpose of medicinal products. Medicinal chemistry is 
a highly interdisciplinary science combining organic chemistry with biochemistry, 
computational chemistry, pharmacology, pharmacognosy, molecular biology, 
statistics and physical chemistry. 
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The second step of drug discovery involves the synthetic modification of the 
hits in order to improve the biological properties of the compound pharmacophore. 
        Heterocyclic chemistry is the chemistry branch dealing exclusively with 
synthesis, properties and application of heterocycles. Heterocyclic compound is an 
organic compound that contains a ring structure containing atom in addition to 
carbon, such as sulfur, oxygen or nitrogen as part of the ring. They may be either 
simple aromatic ring or non-aromatic rings.  Some heterocyclic compounds are 
known as carcinogens.  Researches have show that heterocyclic amines are the 
Carcinogenic  chemicals.  
        A heterocyclic compound is one which possesses a cyclic structure with at least 
two different kinds of hetero atoms in the ring. Nitrogen, oxygen, and sulphur are 
most common hetero atoms. Heterocyclic compounds are very widely distributed in 
nature and are essential to life in various ways. 
1.2. 1, 3, 4- Thiadiazole
2
 
        Many infectious diseases once considered incurable and lethal are now 
amenable. Today a major worldwide problem is resistance towards the available 
drug therefore in order to deal with resistance new compounds has to be synthesized. 
The resistance towards available drugs is rapidly becoming a major worldwide 
problem. The need to design new compounds to deal with this resistance has become 
one of the most important areas of research today. Thiadiazole is a versatile moiety 
that exhibits a wide variety of biological activities. Thiadiazole moiety acts as 
“hydrogen binding domain” and “two-electron donor system”. It also acts as a 
Introduction  
 
 Dept.of Pharmaceutical Chemistry                  4          J.K.K.Nattraja College of Pharmacy 
 
constrained pharmacophore. Many drugs containing thiadiazole nucleus are 
available in the market such as acetazolamide, methazolamide, sulfamethazole, etc. 
Thiadiazole can act as the bio-isosteric replacement of the thiazole moiety. So it acts 
like third and fourth generation cephalosporins, hence can be used in antibiotic 
preparations. Thiadiazole is a 5-membered ring system containing two nitrogen and 
one sulphur atom. They occur in nature in four isomeric forms viz. 1,2,3- 
thiadiazole; 1,2,5-thiadiazole; 1,2,4-thiadiazole and 1,3,4-thiadiazole. 
  Thiadiazole derivatives possess interesting biological activity probably 
conferred to them by the strong aromaticity of this ring system, which leads to great 
in vivo stability and generally, a lack of toxicity for higher vertebrates, including 
humans. When diverse functional groups that interact with biological receptors are 
attached to this ring, compounds possessing outstanding properties are obtained. 
1.3. Chemistry of Thiadiazole moiety: 
  A series of thiadiazole have been synthesized using an appropriate synthetic 
route and characterized by elemental analysis and spectral data.  There are various 
types of thiadiazole rings are present: 
 1, 2, 4-Thiadizole 
 1, 3, 4-Thiadizole 
 1, 2, 5-Thiadizole 
 1, 2, 3-Thiadizole 
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1, 2, 4-Thiadiazole moiety:     
 
  1,2,4 –Thiadiazole moiety contain sulfur at position -1, and two nitrogen 
atom at position -2 & position -4. The photochemistry of 1, 2, 4-thiadiazoles is of 
interest because the ring system can be viewed as a combination of a thiazole and an 
isothiazole 1. 
 
  Therefore, 1, 2, 4-thiadiazoles would be expected to undergo 
phototransposition reaction, via sulfur migration around four sides of the 
photochemically generated bicyclic intermediates, and photocleavage of the S-N 
bond similar to those of thiazoles and isothiazoles. 
1, 3, 4 –Thiadiazole moiety: 
  1,3,4- Thiadiazole moiety contain a heterocyclic nucleus in which sulfur 
present at position -1, and two nitrogen atom at position -3 & position -4.  
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1, 2, 5-Thiadiazole moiety: 
  1,2,5- Thiadiazole moiety contain a heterocyclic nucleus in which sulfur 
present at position -1, and two nitrogen atom at position -2 & position -5. 
1, 2, 3-Thiadiazoles moiety: 
  1,2,3- Thiadiazole moiety contain a heterocyclic nucleus in which sulfur 
present at position -1, and two nitrogen atom at position -2 & position -3.  
 
  Moreover, much interest has also been focused on the cardiotonic, diuretic 
and herbicidal activities displayed by compounds incorporating this heterocyclic 
system1.  
            Thiadiazole is a heterocyclic compound containing both two nitrogen atom 
and one sulfur atom as part of the aromatic five-membered ring. It is a versatile 
moiety that exhibits a wide variety of biological activities. Thiadiazole moiety acts 
as ―hydrogen binding domain‖ and ―two-electron donor system2. Thiadiazoles act 
as bioisosteric replacement of thiazole moiety. It is also bioisosteres of oxadiazole, 
oxazole and benzene. Substitution of these heterocycles with a thiadiazole typically 
Introduction  
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leads to analogues with improved activities because the sulfur atom imparts 
improved liposolubility
3
.  
           Thiadiazole occur in nature in four isomeric forms as 1,2,3-thiadiazole; 1,2,5-
thiadiazole; 1,2,4-thiadiazole and 1,3,4-thiadiazole.The most fully investigated of 
these being the 1,2,4- and 1,3,4-thiadiazoles. Differently substituted thiadiazole 
moieties have different activity. 
            Isomers of thiadiazole compounds that contain thiadiazole ring are 
acetazolamide, methazolamide, sulfamethazole, etc. Other thiadiazole containing 
drugs include, cefazolin sodium (CFZL; and cefazedone (CFZD;)—first-generation 
cephalosporins; timolol—a nonselective β-adrenergic receptor blocker used for the 
treatment of hypertension, angina, tachycardia and glaucoma; xanomeline—a 
selective agonist of muscarinic acetylcholine receptor subtypes M1 and M4 and 
megazolan anti-parasitic drug4. Newly synthesized compounds are SCH-202676 in 
2001 as a promising allosteric modulator of G-protein coupled receptors in 1998, 
KC 12291 as cardio protective action and in 2002 the small heterocyclic 
thiadiazolidinones (TDZD) as the first non-ATP competitive glycogen synthase 
kinase 3β inhibitors5. 
 1.4. Properties of Thiadiazole 
            It is a clear to yellowish liquid with a pyridine like odor. It is soluble in 
alcohol and ether and slightly soluble in water. Thiadiazoles carrying mercapto, 
hydroxyl and amino substituent’s can exist in many tautomeric forms. Metal 
complexes having 1, 3, 4- thiadiazole nucleus has been used as anti- corrosion paints 
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and anti- fouling in marine
6
 Thiadiazole derivatives also possesses fluorescence 
properties
7
. 
           Structure and aromatic properties: Bak et al. analyse the spectra of 1, 3, 4-
thiadiazole and three isotopically substituted species. Using the analysis of 
difference between the measured bond lengths and covalent radii, it was concluded 
that the aromatic character, as measured by the π-electron delocalization decreases 
in the order –1, 2, 5-thiadiazole > thiophene > 1, 3, 4- thiadiazole
8
 Dipole Moment: 
Bak et al. recorded the microwave spectra of 1, 3, 4-thiadiazole (I) and [34S] 1, 3, 4-
thiadiazole (II) in the 15,000–30,000 Mc/sec region and measured the dipole 
moment of 1, 3, 4-thiadiazole in the gas phase by microwave technique and found a 
value of 3.28+-0.03 D9. 
1.5. Method of synthesising thiadiazole  
Synthesis of 1, 3, 4-thiadiazole  
From thio-semicarbazide: 1, 3, 4-thiadiazole can be synthesized by the cyclization 
of thiosemicarbazides10 or ferric ammonium sulphate or ferric chloride catalysed 
oxidation cyclization of thiosemicarbazones11.  
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From arylhydrazide: Desai et al. synthesized various 2, 5-(4-chloro benzyl)-N-
aryl-1, 3, 4- thiadiazole-2-amine by the cyclization of 2-(2-(4-chlorophenyl) acetyl)-
N-aryl hydrazine carbothioamides with sulphuric acid
12
. 
 
Synthesis of 1, 2, 3-Thiadiazole  
  Cyclization of hydrazones with thionyl chloride (Hurd–Mori Synthesis): 
Hydrazone derivatives that are substituted at N-2 with an electron- withdrawing 
group (Z = CONH2, COOMe, COR, SO2R) and possess an adjacent methylene 
group can cyclize in the presence of thionyl chloride to form 1, 2, 3-thiadiazoles. 
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Cycloaddition of diazoalkanes onto a C=S bond (Pechmann Synthesis): When diazo 
compounds react with various thiocarbonyl compounds (thioketones, thioesters, 
thioamides, carbon disulfide, thioketenes, thiophosgene and isothiocyanates) 1, 2, 3-
thiadiazoles are formed. The reaction of diazoalkanes with thioketones gives 
mixtures of 1, 3, 4-thiadiazolines and 1, 2, 3-thiadiazolines
13-14
.  
 
Synthesis of 1, 2, 4-Thiadiazole 
Condensation of aryl thioaides with methyl bromocyanoacetate: 1, 2, 4-thiadiazole can 
be synthesized when methyl bromocyanoacetate was allowed to react with aryl 
thiomide using different solvents. This reaction undergoes rapid condensation and 
provide quantitative yield
15
. 
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Synthesis of 1, 2, 5-Thiadiazole 
   From acetonitrile: Treatment of an acetonitrile solution of the 1,2 3-
dithiazoles with aqueousammonia gave in three cases the corresponding 1,2,5-
thiadiazoles
16-19
.
 
1.6. CANCER AND ANTI CANCER AGENTS 
Today, the Greek term carcinoma is the medical term for a malignant tumour 
derived from epithelial cells. It is celsus who translated carcinos into the Latin 
cancer, also meaning crab. Galen used “oncos” to describe all tumours, the root for 
the modern word oncology.
20, 21
 
 Cancer is an important public health on concern and in developed countries 
it represents the second leading cause of death, after cardiovascular disease. The 
resistance  to  chemotherapeutic  antitumour  agents  by  cancer  cells   could  be 
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minimized using a combination of drugs with different and complementary 
mechanism of action. Therefore, there is a need to discover and develop useful new 
lead compounds of simple structure, exhibiting optimal in vivo antitumour potency 
and new mechanism of action. 
 Cancer is a disease in which a group of cells divides abnormally without 
any control, as to overrun and even destroy other tissues. These cells spread all over 
the body through the blood and lymph, giving rise to satellite lesions elsewhere and 
then eventually leading to death.   
  Cancer is one of the most wide spread and feared diseases in the western 
world today feared largely because it is known to be difficult to cure. The main 
reason for this difficulty is that cancer results from the uncontrolled multiplication of 
subtly modified normal human cells.  
  One of the main methods of modern cancer treatment is drug therapy 
(chemotherapy). Cancer is a major disease about one in four people will get it in 
some form during their life time, and at the present time about one in five of all 
death are due to cancer. 
Currently there are three major ways of treating cancer: 
 Radiation therapy 
 Cytotoxic drugs. 
  Cancer arises from the mutation of a normal gene. Mutated genes that cause 
cancer are called oncogenes. A factor which brings about a mutation is called a 
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mutagen. Any agent that causes a cancer is called a carcinogen and is described as 
carcinogenic. 
 
 
 
 
 
 
 
 
 
Fig.No.1 Types of cancer cell division 
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Types of tumour 
1. Benign tumours (do not spread from their site of origin, but can crowd 
out (squash ) surrounding cells e.g. brain tumour) 
2. Malignant tumours (can spread from the original site and cause 
secondary tumours. this is called metastasis. They interfere with 
neighboring cells and can block blood vessels, the gut, glands, lungs etc.) 
The Cell Cycle 
 
 
 
 
 
 
 
 
Fig.No.2 Phases of Cell cycle 
 The cell cycle consists of four stages G1, S, G2 and M.  
  G1 and G2 are 'gap' phases in which the cell grows and prepares to 
divide. 
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   S in the synthesis phase in which the chromosomes (DNA) are copied 
(replicated).  
 M is the mitotic phase in which the cell physically divides into two 
daughter cells.   
 Most cells are NOT actively dividing. These cells are in a resting state 
(G). 
Mitosis (M phase) 
 Mitosis in normal cells produces two cells with identical genetic content. 
 Mitosis has four sub-phases.   
 Prophase - Chromosomes condense, the nuclear membrane breaks down and 
spindle fibers form  
 Metaphase - The replicated chromosomes line up in the middle of the cell. 
 Anaphase - Chromosomes separate and  the cell becomes elongated   
with distinct ends (poles) 
 Telophase  -  Nuclear  envelopes  reform  at  the  two  poles  and  new  cell 
membranes are formed to create two independent cells 
 Cytotoxicity is the cell killing property of a chemical compounds .cell death 
can occur by either of two distant mechanism, necrosis or apoptosis. 
 Necrosis   is   physical   or   chemical   damage,   where   apoptosis   is   the 
physiological process by which unwanted cells are eliminated during 
development and other normal biological processes. 
 
Introduction  
 
 Dept.of Pharmaceutical Chemistry                  16          J.K.K.Nattraja College of Pharmacy 
 
Types of cancer 
Lung Cancer Lung 
Breast Cancer Breast 
Cervical Cancer Cervical 
Colon  Cancer Colon 
Leukemia Blood 
Testicular Cancer Testis 
Brain Cancer Brain 
Kidney Cancer Kidney 
Thyroid Cancer Thyroid Gland 
Liver Cancer Liver 
Bone Cancer Bone marrow 
 
Table No.1 Types of Cancer 
Causes of cancer 
 DNA Mutations 
1. Radiation – other environmental (tobacco, alcohol, radon, asbestos, 
chemicals etc). 
2. Random somatic mutations 
3.  Inherited germ line mutations 
 Genetic predisposition – 
1. Rb, p53, APC, CDKN2A, BRCA1, BRACA2 
 Infectious agents 
1. Viral 
Introduction  
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A.   HPV(Human papilloma virus) – cervical cancer 
B.  Hepatitis – liver cancer 
2.   Bacterial 
A.  H. pylori – stomach cancer 
 
Diagnosis of cancer 
 Biopsy of the tumor 
 Blood tests (which look for chemicals such as tumor makers) 
 Bone marrow biopsy (for lymphoma or leukemia) 
 Chest x-ray 
 Complete blood count 
 CT scan  &     MRI scan 
Treatment of Cancer Traditional treatment 
1.Surgery: it is the first treatment which is used to removed solid tumors, and 
for early stage cancer and benign tumors. 
2.Radiation: it kills the cancer cells with high energy rays targeted to the 
tumor. It acts by damaging DNA and preventing its replication. 
 Newer treatment 
1. Hormone therapy: by using Hormones and anti – Hormone. 
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2. Chemotherapy: Chemotherapy means treatment with anti cancer drugs 
and they are given to destroy or control cancer cells. 
1.7 CERVICAL CANCER 
 The American Cancer Society’s most recent estimates for cervical cancer in 
the United States are for 2011: 
 About  12,710  new  cases  of  invasive  cervical  cancer  will  be diagnosed 
per year. 
 About 4,290 women will die from cervical cancer per year. 
  Cervical cancer is one of the most common types of cancer and a majority 
mortality factor of women worldwide. 
The cervix is the lower part of the uterus (womb). The part of the cervix 
closest to the body the uterus is called the endocervix. The part next to the vagina is 
the exocervix. The two main types of cells covering the cervix are squamous cells 
(on the endocervix). The place where these two cell types meet is called the 
transformation zone. Most cervical cancers start in the transformation zone. 
Normally, cervical cells grow in an orderly fashion. However, when control 
of that growth is lost, cells divide too frequently and too fast. Nearly all cervical 
cancers arise of the inner of the cervix. 
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There are several types of cervical cancer: 
  Squamous cell carcinoma (SCC) is the most common type of cervical 
cancer, accounting for 85% to 90% of all cases. It develops from the cells that line 
the inner part of the cervix, called the squamous cells. 
  Adenocarcinoma  develops  from  the  column  shaped  cells  that  line  the  
mucous producing glands of the cervix. In rare instances, adenocarcinoma accounts 
for about 10%of all cervical cancers. 
  Mixed c a r c i n o m a s   (adenosquamous  carcinomas)  combine  
features  of  both squamous cell carcinoma and adeno carcinoma. 
 
 
 
 
 
 
 
Fig.No.3 Cervix 
 
 
Introduction  
 
 Dept.of Pharmaceutical Chemistry                  20          J.K.K.Nattraja College of Pharmacy 
 
Treatment of Cervical Cancer 
 Surgery 
 Pre invasive cervical cancer 
 Cryosurgery 
 Laser surgery 
 Conization 
 Invasive cervical cancer 
1. Simple hysterectomy – removal of the body of the uterus and cervix 
2. Radical hysterectomy and pelvic lymph node dissection  Removal of 
entire uterus, surrounding tissue,upper part of the vagina and lymph 
nodes from the cervix. 
 Radiation 
 Chemotherapy 
The drugs used to combat cancer belong to one of the two broad categories. 
The first is cytotoxic drugs (cell killing) and the second is cytostatic drugs (cell 
stabilizing). Both the categories lead to a reduction in the size of tumor because 
cancer cells (for various reasons) have such a high mortality rate that simply 
preventing them from dividing will lead to a reduction in the population. 
The majority of drugs used for treatment of cancer today are cytotoxic (cell 
killing) drugs that work by interfering in some way with the operation of the cell’s 
DNA. Cytotoxic drugs have the potential to be very harmful to the body unless they 
are very specific to cancer cells something difficult to achieve because the  
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modifications that change a healthy cell into a cancerous one are very 
subtle. A major challenge is to design new drugs that will be more selective for 
cancer cells, and thus have lesser side effects. 
The development of a new pharmaceutical is a complex process, but can be 
broken down to three main steps: 
 Discovery of a new potentially use full molecule. 
 Appropriate molecular modification to produce a molecule with the best 
combination of properties. 
 Development of this molecule into a safe and affordable drug.
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Fig.No.4 MOA of Cytotoxic drugs 
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CHAPTER -2 
 
REVIEW OF LITERATURE 
 
 
ANTIMICROBIAL  
  Zamani et al
22
 (2004) has reported new 2, 5-disubstituted derivatives of 1, 3, 4-
thiadiazoles (1) containing isomeric pyridyl were obtained from cyclization of 
corresponding thiosemicarbazides under acidic conditions. Most of the synthesized 
compounds have been found to be active against both gram-positive and gram-negative 
bacteria at less than 3.6 mg/ml. The compound is most active against all seventeen used 
gram-positive and gram-negative bacteria. 
 
(1) 
  Purohit et al
23
 (2011) has reported the synthesis of fused ring system 3-(3-
chlorophenyl)-6-aryl-5,6-dihydro[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles (2) reaction of 
4-amino-5-(3 chlorophenyl)-4H-1,2,4-triazole-3-thiol. All the newly synthesized 
compounds were screened for their antimicrobial activity. Some of the compounds 
exhibited significant inhibition on bacterial and fungal growth as compared to standard 
drugs.  
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(2) 
 
 Zamani et al
24
. (2003) has synthesized a new 1, 2, 4-tri and 1, 3, 4-thiadiazoles (3) 
bearing isomeric pyridyl and 1- naphthyl using 1,4-disubstituted thiosemicarbazides in 
alkaline and acidic media, respectively. The antibacterial studies of some of the 
synthesized compounds against S. aureus and E. coli as MIC values are reported. None 
of them have important antibacterial activities. 
 
(3) 
 Amir et al
25
. (2009) has reported the synthesis of thiosemicardazide of 6-chloro-2-
aminobenzotiazole (4) on cyclization with different carboxylic acid in POCl3 and 
substituted azalactones in pyridine provide the corresponding 2-aryl-5-(6chloro-
1,3benzothiazole-2-yl-amino)- 1,3,4-thiadiazoles. All the compounds have been 
evaluated in vitro for their antimicrobial activities against several microbes and show 
significant activity.  
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(4) 
 
  Otilia Pintilie and co-workers
26
 (2007) has reported the new synthesis that is 
1,3,4-thiadiazole(5) and 1,2,4-triazolecompounds containing a D,L-methionine moiety 
(5) were synthesized by intramolecular cyclization of 1,4-disubstituted 
thiosemicarbazides in acid and alkaline media, respectively.  
 
(5) 
 
ANTIHELMINTHICS 
  Parmar Kokila and co-workers
27
 (2011) has prepared a new and biologically 
active [1,2,4] triazolo [3,4-b][1,3,4] thiadiazole-2-aryl-thiazolidinone-4-ones (6) by 
reaction of Schiff bases with mercapto acetic acid in presence of THF with adding 
anhydrous ZnCl2. The compounds have been evaluated for antibacterial activity against 
B. subtilis, S. aureus, P. aeruginosa. 
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(6) 
 
  Mathew et al
28
 (2010) has synthesiszed some Schiff bases of 5-phenyl 
substituted, 2-amino 1, 3, 4 thiadiazole derivatives (7). This reaction between various 
aryl carboxylic acids with thiosemicarbazide in presence of dehydrating agent like 
Conc. H2SO4 to form 5-phenyl substituted, 2-amino 1, 3, 4 thiadiazole derivates. These 
derivatives on further treatment with various aldehydes to form Schiff base. 
 
(7) 
ANTI INFLAMMATORY 
  Varandas et al
29
, (2005)  has reported design, synthesis and evaluation of the 
anti-inflammatory, analgesic, and antiplatelet properties of new 1,3,4-thiadiazole 
derivatives (8), structurally planed by exploiting the molecular hybridization approach 
between diuretic drug acetazolamide and a 1,3-benzodioxole COX-2 inhibitor, 
previously developed. The in vivo pharmacological evaluation of these new compounds 
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lead us to identify the para-fluoro-substituted derivative 8b as a new prototype, more 
active that celecoxib at the same molar concentration. 
 
(8) 
  Schenone et al
30
 (2001) has prepared the series of 3-arylsulphonyl-5-arylamino-
1,3,4-thiadiazol-2(3H)ones (9) with potential anti-inflammatory and analgesic activity. 
Pharmacological results revealed that all the title compounds, endowed with an 
arylsulphonyl side chain, possess good antalgic activity and fair anti-inflammatory 
properties. The analgesic profile of the two series, evaluated by the acetic acid writhing 
test, showed that compouds 2c, 2f and 2h, in particular, were the most active.  
 
(9) 
  Amir and co-workers
31
 (2007) has reported various 1,3,4-oxadiazoles, 1,2,4-
triazoles, 1,3,4-thiadiazoles, and 1,2,4- -triazine derivatives of ibuprofen by cyclization 
of 2-(4-butyl phenyl) propionic acid hydrazide and N1-[2-(4-i- butylphenyl)-propionyl]-
N4-alkyl/aryl- -thiosemicarbazides under various reaction conditions. The cyclized 
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derivatives were screened for their anti-inflammatory activity by the carrageenan 
induced rat paw edema method and showed 50 to 86% inhibition, whereas the standard 
drug ibuprofen showed 92% inhibition at the same oral dose.  
  Varandas et al
32
 (2010) has reported a design, synthesis and evaluation of the 
anti-inflammatory, analgesic, and antiplatelet properties of new 1,3,4-thiadiazole 
derivatives, structurally planed by exploiting the molecular hybridization approach 
between diuretic drug acetazolamide and a 1,3-benzodioxole COX-2 inhibitor, 
previously developed. The in vivo pharmacological evaluation of these new compounds 
lead us to identify the para-fluoro-substituted derivative 8b as a new prototype, more 
active that celecoxib at the same molar concentration. 
 
ANTIVIRAL 
  Chen et al
33
 (2010) has reported a synthesis of new 5-(4 chlorophenyl)-N-
substituted-N- 1, 3, 4-thiadiazole-2- sulfonamide derivatives in six-steps. Esterification 
of 4-chlorobenzoic acid (10) with methanol and subsequent hydrazination, salt 
formation and cyclization afforded 5-(4-chlorophen-yl)-1, 3, 4-thiadiazole-2- thiol. 
Conversion of this intermediate into sulfonyl chloride, followed by nucleophilic attack 
of the amines gave the title sulfonamides.   
 
(10) 
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  Friedrick and Hayden et al
34
 (1994)  has reported the efficacy and safety of oral 
LY217896 for prevention of experimental influenza A/Kawasaki/86 (HIN1) virus 
infection were assessed in susceptible males randomly assigned to receive LY217896 
(75 mg) or placebo once daily for 7 days beginning 24 h prior to viral challenge. The 
rates of virus shedding (100% in both groups), days of viral shedding (3.1 ± 1.3 for the 
LY217896 group; 2.8 ± 1.3 for the placebo group), and titers of virus in nasal washings 
did not differ between the groups. Mild upper respiratory tract illness (72% in the 
LY217896 group; 69% in the placebo group) developed in similar proportions of each 
group. LY217896 was associated with asymptomatic rises in serum uric acid levels and 
was ineffective in modifying the virologic or clinical course of experimental influenza 
A (HiN1) virus infection.  
 Jones et al
35
 (2009) has prepared Isosorbide-2-aspirinate-5-salicylate is a true 
aspirin prodrug in human blood because it can be effectively hydrolyzed to aspirin upon 
interaction with plasma BuChE. It shows that the identity of the remote 5-ester dictates 
whether aspirin is among the products of plasma-mediated hydrolysis. By observing the 
requirements for aspirin release from an initial panel of isosorbide-based esters, it is 
able to introduce nitro oxy methyl groups at the 5-position while maintaining ability to 
release aspirin. Several of these compounds are potent inhibitors of platelet aggregation. 
The design of these compounds will allow better exploration of cross-talk between 
COX inhibition and nitric oxide release and potentially lead to the development of 
selective COX-1 acetylating drugs without gastric toxicity.  
  Bonina et al
36
 (1982) has reported preparation of 2-amino-5-(2-
sulfamoylphenyl)- 1,3,4-thiadiazole(11) (G413) was shown to possess high activity 
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against DNA viruses (herpes simplex viruses 1 and 2 and adenovirus 17 and RNA 
viruses (poliovirus 1, echovirus 2, and cox sickie virus B4) experiments on the 
replicative cycle of poliovirus 1 and production of infectious RNA viruses demonstrate 
that this compound probably prevents assembly of virus particles by acting on structural 
proteins. In the present experiments, results concerning the activity of derivatives of G-
413 after side-chain modification are reported. Modification of the primary amine H to 
CH3 or CH2-CH=CH2 produced a loss of activity against DNA viruses, but inhibitory 
action on RNA viruses was preserved. Modification to CH2CH3 resulted in the loss of 
antiviral activity.  
 
ANTICANCER 
  Şerban and coworkers37 (2010) has reported some 2-R-5-formyl-1,3,4-
thiadiazole derivatives (11) have been synthesized and characterized by their spectral 
data  through Sommelet reaction, of some hexamethylenetetramine salts from which 
some new heterocyclic aldehydes resulted. 
Ilango et al
38
 (2010) has prepared a facile synthesis of 3, 6‐disubstituted‐ 1, 2, 
4‐triazolo‐ [3, 4‐b] ‐1, 3, 4‐ thiadiazoles) by condensing 3‐aryl substituted 
4‐amino‐5‐mercapto (4H)‐1, 2, 4‐triazole with various aromatic acids. 
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(11) 
  Sahu and co-workers
39
 (2013) has reported the substituted salicylic acid and 
thiosemicarbazide were refluxed in acidic medium to obtain 2-amino-5-(o-
hydroxysubstituted phenyl)-1, 3, 4-thiadiazol which on treatment with various aryl 
aldehydes and then with thioglycolic acid gives 2-(substitutedphenyl)-3-(2-
hydroxysubstitutedphenyl-1,3,4-thiadiazol-2yl) thiazolidin-4-ones. Structures of the 
compounds (3a-l) were confirmed on the basis of IR and 1HNMR data. All the 
compounds were tested against Staphylococcus areus, Pseudomonas aeruginosa, 
Candida albicans and Aspergillus niger.  
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CHAPTER -3 
RESEARCH ENVISAGED 
3.1 Objective of the Present Work 
 
           1, 3, 4-thiadiazole possess a wide spectrum of biological and pharmacological 
activity due to the presence of nitrogen and sulfur axis which is considered to be 
responsible for the structural features to impart their activities 
 
Despite the optimal use of available anti-cancer drugs (ACDs), many patients with 
cancer fail to experience neoplasmic control and others do so only at the expense of 
significant toxic side effects. The limitations with the conventional ACDs highlighted the 
need for developing newer agents to treat cancer and therefore new, less toxic and more 
effective drugs are required. Based on the bioisostere concept in the present study we 
explored 1, 3, 4-thiadiazole as a pharmacophore for the development of new anticancer 
drugs. 
1, 3, 4-Thiadiazoles  are five membered ring system containing sulphur and 
nitrogen atom and received much attention of medicinal chemists due to their potential 
biological activities. Various substituents at C-2 and C-5 of thiadiazoles results in potent 
anticancer activity. Prompted by these reports, we aimed to prepare the following series of 
2, 5-disubstituted-1, 3, 4-thiadiazole derivatives as potent anti-cancer agents. 
 Hence the specific aims & objectives of the present study are, 
 To synthesize a series of novel 2, 5-disubstituted thiadiazoles. 
 To characterize the synthesized compounds by IR, NMR, Mass spectra and elemental 
analysis. 
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 To evaluate the test compounds for  in vitro anti-cancer activity by  
 MTT in vitro assay method 
The title compounds are planned to synthesize by using the following synthetic routes 
mentioned in the following Schemes.   
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SCHEME 
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CHAPTER – 4 
 
 
 
4.1EXPERIMENTAL WORK 
 
 
4.1.1MATERIALS AND METHODS 
 
  Melting points (mp) were taken in open capillaries on Thomas 
Hoover melting point apparatus and are uncorrected. The IR spectra were recorded 
in film or in potassium bromide disks on a Perkin-Elmer 398 spectrometer. The 1H 
spectra were recorded on a DPX-500 MHz Bruker FT-NMR spectrometer. The 
chemical shifts were reported as parts per million (δ ppm) tetramethylsilane (TMS) 
as an internal standard. Mass spectra were obtained on a JEOL-SX-102 instrument 
using fast atom bombardment (FAB positive). Elemental analysis was performed on 
a Perkin-Elmer 2400 C, H, N analyzer and values were within the acceptable limits 
of the calculated values. The progress of the reaction was monitored on readymade 
silica gel plates (Merck) using chloroform-methanol (9:1) as a solvent system. 
Iodine was used as a developing agent. Spectral data (IR, NMR and mass spectra) 
confirmed the structures of the synthesized compounds and the purity of these 
compounds was ascertained by microanalysis. Elemental (C,H,N) analysis indicated 
that the calculated and observed values were within the acceptable limits (± 0.4%). 
All chemicals and reagents were obtained from Aldrich (USA), Lancaster (UK) or 
Spectrochem Pvt.Ltd (India) and were used without further purification. 
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4.1.1.1. General Procedure for synthesis of 5-aryl -1, 3, 4-thiadiazol-2-amine (I).    
  A mixture of thiosemicarbazide (0.1mol) and aryl carboxylic acid (0.1mol) 
in conc.sulphuric acid (10 drops) was refluxed for 1 hr & poured onto crushed ice. 
The solid separated out was filtered, washed with water & recrystallized from 
ethanol.  
4.1.1.2. General Procedure for synthesis of substituted N-(5-aryl-1, 3,4-
thiadiazole-2-yl)-2-chloroacetamide (II)  
  Substituted amino compounds (0.3mol) were dissolved in glacial acetic acid 
(20ml) containing 20ml of saturated solution of sodium acetate. In case the 
substance did not dissolve completely, the mixture was warmed and the solution was 
cooled in ice bath with stirring. To this chloroacetyl chloride was added drop wise 
(0.06mol) with stirring. After half an hour white product separated and filtered. The 
product was washed with 50% aqueous acetic acid and finally with water. It was 
purified by recrystallization from ethyl alcohol.  
4.1.1.3. General Procedure for synthesis of substituted N-(5-aryl-1, 3, 4-
thiadiazole-2-yl)-2-alkyl / aryl substituted acetamides (TZ 1-10)  
  A mixture of N-(5 aryl-1, 3, 4-thiadiazole-2-yl)-2-chloroacetamide 
(0.01mol) is taken in 25ml of ethyl alcohol and alkyl and aryl substituted derivatives 
(0.01mol) were added and refluxed for 4hr. The resulting mixture was purified by 
recrystallization from alcohol.  
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4.1.2. Synthesis of 5-p-tolyl-1, 3, 4-thiadiazol-2-amine (I) 
Yield                              : 2.46 g; 91.0 %  
Melting Point                 : 156-159 °C 
Rf Value                         : 0.86 (benzene: ethyl acetate (8:2)      
Molecular Formula       : C9H9N3S 
Molecular Weight         : 191(M+) 
IR (KBr) cm
-1                         
: 3290 (NH2), 3045 (Ar-CH), 1620 (C=N   
                                          Str),  675 (C-S-C).                                           
1
H NMR (CDCl3) δ ppm   : 1H NMR (CDCl3) δ (ppm): 2.35 (s, 3H, CH3), 4.02(s,  
                                            2H, NH2), 7.12 (d, J = 8.0 Hz, 2H, Ar-H), 7.36 (d, J =  
                                            8.0Hz, 2H, Ar-H).  
Elemental Analysis 
Calculated                      : C, 56.52; H, 4.74; N, 21.97.  
Found                              : C, 56.50; H, 4.73; N, 21.95.  
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4.1.3. Synthesis of 5-(4-bromophenyl)-1, 3, 4-thiadiazol-2-amine (Ia)  
Yield                               : 2.57 g; 76.0 %  
Melting Point                  : 197-199 °C 
Rf Value                         : 0.74 (benzene: ethyl acetate (8:2)      
Molecular Formula         : C8H6BrN3S 
Molecular Weight            : 256(M+), 258 (M+2) 
IR (KBr) cm
-1                         
: 3290 (NH2), 3045 (Ar-CH), 1620 (C=N   
                                          Str),  675 (C-S-C), 651 (C-Br).                                          
1
H NMR (CDCl3) δ ppm   : 1H NMR (CDCl3) δ (ppm): 4.12 (s, 2H, NH2), 7.37 (d,   
                                            J = 8.0 Hz, 2H, Ar-H), 7.49 (d, J = 8.0Hz, 2H, Ar-H).  
Elemental Analysis 
Calculated                       : C, 37.52; H, 2.36 ; N, 16.41.  
Found                             : C, 37.51; H, 2.34; N, 16.40. 
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4.1.4. Synthesis of 2-chloro-N-(5-methyl-1,3,4-thiadiazol-2-yl)acetamide (II). 
Yield                             : 2.10 g; 69.0 %  
Melting Point                 : 142-145 °C 
Rf Value                       : 0.72 (benzene: ethyl acetate (8:2)     
Molecular Formula        : C5H6ClN3OS 
Molecular Weight               : 191(M+) 
IR (KBr) cm
-1                      
:  3426 (NH), 3040 (Ar-CH), 1710(C=O),1617 (C=N                   
                                           Str), 674 (C-S-C).                                          
1
H NMR (CDCl3) δ ppm    : 1H NMR (CDCl3) δ (ppm): 2.37(s, 3H, CH3), 4.27 (s,   
                                              2H, CH2), 7.12 (d,J = 8.0 Hz, 2H, Ar-H), 7.36 (d, J =  
                                              8.0Hz, 2H, Ar-H), 8.02 (s, 1H, NH).                                      
Elemental Analysis 
Calculated                           : C, 31.34; H, 3.16 N, 21.93. 
Found                                  : C, 31.31; H, 3.15 N, 21.90.  
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4.1.5. Synthesis of N-(5-bromo-1, 3, 4-thiadiazol-2-yl) - 2-chloroacetamide (IIa) 
Yield                                       : 2.38 g; 79.0 %  
Melting Point                          : 208-210 °C 
Rf Value                                 : 0.68 (benzene: ethyl acetate (8:2)     
Molecular Formula       : C4H3BrClN3OS      
Molecular Weight         : 256(M+);258(M+2) 
IR (KBr) cm-1                                      : 3432 (NH), 3058 (Ar-CH), 1708(C=O),1626 (C=N                   
                                           Str), 683 (C-S-C), 631(C-Br).                                         
1H NMR (CDCl3) δ ppm        : 1H NMR (CDCl3) δ (ppm): 4.28 (s, 2H, CH2), 7.35   
(d, J = 8.0 Hz, 2H, Ar-H), 7.45 (d, J = 8.0Hz, 2H, Ar-
H).   8.0 (s, 1H, NH).                                    
Elemental Analysis  
Calculated                               : C, 18.73; H, 1.18; N, 16.38.   
Found                                      : C, 18.71; H, 1.17; N, 16.35.     
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4.1.5. Synthesis of 2-(dimethylamino)-N-(5-p-tolyl-1,3,4-thiadiazol-2-
yl)acetamide(TZ1) .     
Yield                              : 1.92 g; 70.2 %  
Melting Point                 : 150-153 °C 
Rf Value                        : 0.73 (benzene: ethyl acetate (8:2)      
Molecular Formula        : C13H16N4OS      
Molecular Weight           : 276(M+) 
IR (KBr) cm
-1             
:3457(NH),3056(Ar-CH),2929(N(CH3)2,   
                                         1716(C=O),1622 (C=Nstr), 651 (C-S-C).                                          
1
H NMR (CDCl3) δ ppm : 1H NMR (CDCl3) δ (ppm): 2.27 ( d, 3H, CH3), 
2.35(s, 3H, CH3), 3.25 (s, 2H,CH2), 7.14(d, J = 8.0 
Hz,2H, Ar-H), 7.34 (d, J =8.0Hz,2H, ArH), 8.06 
(s,1H,NH). 
Elemental Analysis 
Calculated                          : C, 56.50; H, 5.84; N, 20.27.   
Found                                 : C, 56.48; H, 5.84; N, 20.25.     
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4.1.6. Synthesis of 2-(pyrrolidino)-N-(5-p-tolyl-1, 3, 4 -thiadiazol-2-yl) 
acetamide(TZ 2).     
Yield                                       : 1.88 g; 67.4 %  
Melting Point               : 184-186 °C 
Rf Value                       : 0.77 (benzene: ethyl acetate (8:2)      
Molecular Formula       : C15H18N4OS      
Molecular Weight        : 302(M+) 
IR(KBr)cm-1       :   3478(NH), 3042(Ar-CH), 2926(CH2),  
                                                   1704(C=O),1647 (C=Nstr), 693 (C-S-C).                                           
1H NMR (CDCl3) δ ppm : 1H NMR (CDCl3) δ (ppm): 1.59 (d, 2H, CH2), 2.25   
(d, 2H, CH2), 2.32(s,3H,CH3), 3.24(s,2H,CH2), 7.14 
                                            (d, J= 7.5 Hz, 2H, Ar-H),7.38(d, J = 8.0 Hz, 2H, Ar-   
                                            H), 8.06(s,1H,NH).            
Elemental Analysis 
Calculated                         : C, 59.58; H, 6.00; N, 18.51.   
Found                                 : C, 59.56; H, 5.99; N, 18.53.      
                               
  
 
 
 
Experimental Work  
 
Dept.of Pharmaceutical Chemistry                 43            J.K.K.Nattraja College of Pharmacy 
 
4.1.7. Synthesis of 2-(piperidino)-N-(5-p-tolyl-1, 3, 4 -thiadiazol-2-yl) acetamide 
(TZ 3).     
Yield                              : 1.78 g; 62.4 %  
Melting Point                          : 216-218 °C 
Rf Value                       : 0.82 (benzene: ethyl acetate (8:2)      
Molecular Formula                 : C16H20N4OS     
Molecular Weight          : 316 (M+)  
IR (KBr) cm
-1                                      
: 3418 (NH),3057 (Ar-CH),                     
2929(CH3)1714(C=O),1629  (C=N Str), 689 (C-S-C),    
1
H NMR (CDCl3) δ ppm : 1H NMR (CDCl3) δ (ppm): 1.50 (d, 2H, CH2), 2.24 
(s,  2H, CH2), 2.25 (s, 2H, CH2) 2.35(s,3H,CH3),   
3.27(s,2H,CH2), 7.10(m, J= 7.5 Hz, 4H, Ar-
H),7.66(m, J = 8.0 Hz, 8H, Ar- H), 8.01(s,1H,NH).                                   
Elemental Analysis 
Calculated                     : C, 60.73; H, 6.37; N, 17.71.      
Found                                      : C, 60.0; H, 6.36; N, 17.69.       
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4.1.8. Synthesis of 2-(imidazolo)-N-(5-p-tolyl-1, 3, 4-thiadiazol-2-yl) acetamide 
(TZ 4). 
Yield                                   : 1.68 g; 66.4 %  
Melting Point                     : 190-192 °C 
Rf Value                             : 0.69 (benzene: ethyl acetate (8:2)      
Molecular Formula             : C14H13N5OS 
Molecular Weight                    : 299 (M+) 
IR (KBr) cm
-1                              
: 3417(NH), 3058 (Ar-CH), 2929(CH3), 1710(C=O),    
                                                    1626 (C=N Str), 689 (C-S-C).   
1
H NMR (CDCl3) δ ppm  : 1H NMR (CDCl3) δ (ppm): 2.32 (s,3H,CH3),  
                                            3.52(s,2H,CH2), 6.88 (s, 1H,CH), 7.0(s,                       
                                            1H,CH) 7.12(d, J= 7.5 Hz, 2H, Ar-H),7.35(d,J=8.0Hz,   
                                            4H, Ar- H), 7.45 (s, J=8.0Hz 4H,CH), 8.03(s,1H,NH).   
Elemental Analysis   
Calculated                          : C, 56.17; H, 4.38; N, 23.40 
Found                                 : C, 56.15; H, 4.37; N, 23.38 
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4.1.9. Synthesis of 2-(morpholino)-N-(5-p-tolyl-1,3,4-thiadiazol-2-yl) acetamide 
(TZ 5).     
Yield                            : 1.88 g; 70.5 %  
Melting Point               : 204-206 °C 
Rf Value                      : 0.74 (benzene: ethyl acetate (8:2)      
Molecular Formula      : C15H18N4O2S  
Molecular Weight         : 318 (M+)  
IR (KBr) cm
-1                       
: 3465(NH), 3058 (Ar-CH), 3058(CH3), 1702(C=O),    
                                     1620(C=N Str), 689 (C-S-C).   
1
H NMR (CDCl3) δ ppm: 1H NMR (CDCl3) δ (ppm): 2.34 (s,3H,CH3),2.37    
                                      (s,2H,CH2), 3.25(s,2H,CH2),3.67(d,2H,CH2), 7.12(m,   
                                      J=7.5Hz,4H,Ar-H),7.34(m,J=8.0Hz,8H,Ar-H),   
                                      8.05(s,1H,NH).     
Elemental Analysis 
Calculated                    : C, 56.58; H, 5.70; N, 17.60.     
Found                           : C, 56.56; H, 5.69; N, 17.58. 
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4.1.10. Synthesis of N-(5-(4-bromophenyl)-1, 3, 4-thiadiazol-2-yl)-2 
(dimethylamino) acetamide (TZ 6).      
Yield                              : 1.92 g; 80.1 %  
Melting Point                  : 157-159 °C 
Rf Value                        : 0.75 (benzene: ethyl acetate (8:2)      
Molecular Formula        : C12H13BrN4OS  
Molecular Weight           : 341(M+), 343 (M+2) 
IR (KBr) cm-1                        : 3420(NH), 3050 (Ar-CH), 2816(CH3), 1713(C=O),    
                                         1626(C=N Str), 689 (C-S-C), 654(C-Br).    
1H NMR (CDCl3) δ ppm  : 1H NMR (CDCl3) δ (ppm): 2.27 (d, 6H, CH3), 3.24 
(s, 2H, CH2), 7.37 (d, J = 8.0Hz, 2H, Ar-H),7.69 (d, 
2H, Ar-H), 8.02 (s,1H, NH).  
Elemental Analysis 
Calculated                      : C, 42.24; H, 3.84; N, 16.42. 
Found                             : C, 42.22; H, 3.84; N, 16.40.  
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4.1.11. Synthesis of N-2-(Pyrolidino) (5-(4-bromophenyl)-1, 3, 4-thiadiazol-2-yl) 
acetamide (TZ 7). 
Yield                                : 1.58 g; 62.8 %  
Melting Point                           : 130-134 °C 
Rf Value                        : 0.59 (benzene: ethyl acetate (8:2)      
Molecular Formula        : C14H15BrN4OS       
Molecular Weight          : 367(M+), 369(M+2) 
IR (KBr) cm-1                        : 3442(NH), 3042(Ar-CH), 2946(CH2),  
                                        1704(C=O),1647 (C=Nstr), 672 (C-S-C), 654(C-Br).                                
  
1
H NMR (CDCl3) δ ppm : 1H NMR (CDCl3) δ (ppm): 1.59 (d, 2H, CH2), 2.25 
(d, 1H, OH),3.23 (s, 2H, CH2), 7.36(d, J=8.0                                
                                       Hz, 2H, Ar-H),7.48(d, J=8.0Hz, 2H, Ar-H),   
                                       8.01(s,1H,NH).  .                            
Elemental Analysis  
Calculated                     : C, 45.78; H, 4.12; N, 15.26.      
Found                            : C, 45.76; H, 4.11; N, 15.25.        
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4.1.12. Synthesis of N-2-(Piperidino)(5-(4-bromophenyl)-1, 3, 4-thiadiazol-2-yl) 
acetamide (TZ 8).      
Yield                              : 1.89 g; 76.5 %  
Melting Point                : 212-214 °C 
Rf Value                        : 0.88 (benzene: ethyl acetate (8:2)  
Molecular Formula       : C9H13BrN4OS    
Molecular Weight         : 305 (M+); 307(M+2)   
IR (KBr) cm
-1                        
: 3443 (NH),3057 (Ar-CH),       
2989(CH3)1714(C=O),1629  (C=N Str), 689  (C-S-
C),659(C-Br).  
1
H NMR (CDCl3) δ ppm : 1H NMR (CDCl3) δ (ppm): 1.52( d, 2H,CH2), 2.24 (s,   
                                      2H, CH2), 6.21 (d,8H, CH2), 7.37 (d, J = 8.0 Hz, 2H,  
                                      Ar-H), 7.45 (d, J = 8.0 Hz, 2H, Ar-H), 8.02(s,1H,NH).    
Elemental Analysis 
Calculated                                : C, 35.42; H, 4.29; N, 18.36.       
Found                                      : C, 35.40; H, 4.28; N, 18.34.       
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4.1.13. Synthesis of N-2-(Piperidino)(5-(4-bromophenyl)-1, 3, 4-thiadiazol-2-yl) 
acetamide (TZ 9).      
Yield                              : 1.46 g; 80.7 %  
Melting Point                : 205-207 °C 
Rf Value                       : 0.79 (benzene: ethyl acetate (8:2)  
Molecular Formula       : C7H6BrN5OS     
Molecular Weight         : 288 (M+); 290 (M+2)  
IR (KBr) cm
-1                        
: 3478 (NH),3050 (Ar-CH), 
2929(CH3)1710(C=O),1626   
                                      (C=N Str), 689 (C-S-C), 653(C-Br). 
1
H NMR (CDCl3) δ ppm : 1H NMR (CDCl3) δ (ppm): 3.44 (s, 2H, CH2), 6.21 
(d, 2H, CH2),  7.01 (s, 2H, CH), 7.36(d, J = 8.0  
Hz,2H,  Ar-  H),7.47 (d, J =7.0Hz, 2H, Ar-H), 
8.0(s,1H,NH). 
Elemental Analysis 
Calculated                     : C, 29.18; H, 2.10; N, 24.31.        
Found                            : C, 29.15; H, 2.10; N, 24.29. 
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4.1.14. Synthesis of N-2-(Morpholino) (5-(4-bromophenyl)-1, 3, 4-thiadiazol-2-
yl) acetamide (TZ 10).      
Yield                               : 1.65 g; 73.8 %  
Melting Point                  : 226-228 °C 
Rf Value                          : 0.83 (benzene: ethyl acetate (8:2)  
Molecular Formula           : C8H11BrN4O2S  
Molecular Weight           : 307 (M+); 309 (M+2)  
IR (KBr) cm
-1                        
: 3474 (NH),3058 (Ar-CH), 
2876(CH3)1712(C=O),1620   (C=N Str), 689 (C-S-C), 
655(C-Br).  
1
H NMR (CDCl3) δ ppm : 1H NMR (CDCl3) δ (ppm): 2.90 (d, 4H, CH2), 3.42 
(s, 2H, CH2), 3.65 (s, 4H, CH2), 7.37-(d, J = 8.0  
Hz,2H,  Ar-H),7.49 (d, J =7.0Hz, 2H, Ar-H), 
8.02(s,1H,NH). 
Elemental Analysis 
Calculated                     : C, 31.28; H, 3.61; N, 18.24.        
Found                             : C, 31.26; H, 3.61; N, 18.22. 
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4.2. CHROMATOGRAPHY STUDIES OF SYNTHESIZED COMPOUNDS 
 
4.2.1 THIN LAYER CHROMATOGRAPHY 
 
 Thin Layer Chromatography or TLC is a solid-liquid form of 
chromatography here the stationary phase is a polar absorbent and the mobile 
phase can be a single solvent or Combination of solvents. TLC is inexpensive 
technique and quick that can be used for determine the number of components in 
a mixture, verify a substance’s identity, monitor the process of a reaction, 
determine appropriate condition for column chromatography, analyze the fractions 
obtained from column chromatography. 
 
4.2.1.1 MATERIALS AND METHODS 
 
1. Preparation of plates 
 
 Silica gel G was mixed in a glass mortar to smooth consistency with the 
requisite amount of water and slurry was quickly transferred to the spreader. The 
mixtures have been spread over the plates in thickness of 0.2 mm and allow 
setting into a suitable holder and after 30 minutes, plates were dried at 120
o
C, for 
further activation of the absorbent. 
 
2. Sample application 
 
 About 2 mm of absorbent from the edge of plate was removed to give 
sharply defined edges. 2-5 µ l volumes of synthesized compounds were spotted 
with the help of capillary tubes, just above 1 cm of the bottom of coated plates. 
 
3. Development chamber 
 
 
 The chromatographic chamber was lined with filter paper dipping into 
mobile phase  so  as  to  maintain  the  atmospheric  saturation  with  solvent  
vapors  in  the chamber.  
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4. Solvent system 
 The choice of best developing solvent is one of the most important 
decisions in practical TLC by review of literature survey on by knowing nature of 
compounds, this solvent system used is benzene: ethyl acetate (8:2). 
 
5. Detection of components 
 
 The spots were visualized under Iodine chamber. 
 
4.2.2 COLUMN CHROMATOGRAPHY 
 
 Purification of synthesized derivatives was done by column chromatography. 
Materials 
 
 1.   Glass column of size 45 cm x 3cm. 
 
 2.   Silica gel for column chromatography 60-120 mesh size. 
 
 3.   Eluting solvent system benzene: ethyl acetate (8:2).  
 
Preparation of column 
 
 The silica gel 60-120 mesh size was made into slurry with the above solvent 
system. The bottom of the column was plugged with little glass wool. Then the 
slurry was poured into the column, which is filled with solvent after two third of 
the column areas were filled with slurry. It was set aside for 30 minutes and eluting 
solvent was passed through column for several times ensure good packing of the 
column. After the adsorbents are settled, a filter paper was kept to prevent 
disturbance of the top layer of the adsorbent as fresh mobile phase to be added to 
column for the process of elution. The fractions were collected for every 5 ml and 
analyzed for the presence of different of similar compound by running TLC and 
then allow evaporating to get the residue. 
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4.3. PHARMACOLOGICAL SCREENING 
4.3.1. IN-VITRO ANTI-CANCER ACTIVITY 
          Tissue culture has been used  to screen may anti cancer drugs since  there  is 
clear correlation  between  the in  vitro and in  vivo activities  of  potential  
chemotherapeutic agents.  There  is  scientific  justification  for  cytotoxicity  testing  
in  tissue,  since  animal models are  in many ways  in adequate for predicting  the 
effects of chemicals on humans since there are many metabolic differences between 
species. 
          Cytotoxicity studies involve the analysis of morphological damage or 
inhibition of zone of outgrowth induced by the chemicals tested. 
ASSAY FOR PROLIFERATION STUDIES 
IN VITRO ANTI CANCER ACTIVITY 
          The human cervical cancer cell line (HeLa) was obtained from national center 
for cell  science  (NCCS),  pune. The HeLa  cells were grown  in Eagles Minimum 
Essential Medium  containing  10%  fetal  bovine  serum  (FBS)  and maintained  at  
37°C,  5% CO2, 95% air and 100%  relative humidity. Maintenance cultures were 
passaged weekly, and the culture medium was changed twice a week. 
        Toxicity  of  test  compound  in  cells  was  determined  by  MTT  assay  based  
on mitochondrial  reduction  of  yellow  MTT tetrazolium  dye  to  a  highly  colored  
blue formazan product
40
. 
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Assay for Proliferation Studies - MTT Assay 
Principle  
MTT [(3-(4,5-dimethyl thiazol-2yl)-2,5diphenyl tetrazolium bromide] 
measures the metabolic activity of the viable cells. The assay can be performed 
entirely in a microtiterplate (MTP). It is suitable for measuring cell proliferation, 
Cell viability or Cytotoxicity. The reaction between MTT and mitochondrial 
dehydrogenase produces water-insoluble formazan salt. This method involves 
culturing the cells in a 96 well microtiterplate and then incubating with MTT 
solution for approximately 2 hours. During incubation period, viable cells convert 
MTT to a water insoluble formazan dye. The formazan dye in the MTP is 
solubilized and quantified with an ELISA plate reader. The absorbance directly 
correlates with the cell number. This is applicable for adherent cells cultured in 
MTP. 
Materials for MTT assay 
 The human cervical cancer cell line (HeLa)  
 Eagles Minimum Essential Medium containing 10% fetal bovine 
serum (FBS) 
 Phosphate buffered saline (PBS) 
 Dimethyl sulphoxide (DMSO) 
 MTT [(3-(4,5-dimethylthiazol-2yl)-2,5 diphenyltetrazoliumbromide] 
 CO2 incubator (WTC Binder, Germany) 
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 Laminar air flow cabin (Klenzaids, Chennai, India ) 
 Refrigerated centrifuge ( Biofuge fresco, Heraeus, Germany ) 
 ELISA-reader ( For MTP ) Anthos 2010, Germany ) 
 Deep freezer (Polar Angelantioni Industries, Italy ) 
 Ultrazonic bath ( Transonic [ 460/H ], by Elma, Germany ] 
 Vaccum pump ( Zenith [model: PDF-2-2.5], Mumbai, India ) 
 Pipettes (Eppendoff, Hamburg, Germany ) 
 Culture plates 
 Centrifuge tubes 
 Aerosol resistant tips 
 Flat-bottomed 96-MTP 
 Tissue culture grade 
Cell treatment procedure 
          Cell treatment procedure The monolayer  cells were detached with  trypsin-
ethylenediaminetetraacetic  acid (EDTA)  to  make  single  cell  suspensions  and  
viable  cells  were  counted  using  a hemocytometer  and  diluted with medium with  
5%  FBS  to  give  final  density  of  1x105 cells/ml.  one  hundred microlitres  per 
well  of  cell  suspension were  seeded  into  96-well plates at plating density of 
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10,000 cells/well and incubated to allow for cell attachment at 370 C, 5% CO2, 95%  
air  and 100%  relative humidity.  
        After 24 h the cells were  treated with  serial concentrations of  the extracts and  
fractions. They were  initially dissolved  in neat  dimethylsulfoxide  (DMSO)  and  
further  diluted  in  serum  free medium  to  produce five concentrations. One 
hundred microlitres per well of each concentration was added to plates to obtain 
final concentrations of 100, 10, 1.0 and 0.1 µM. The final volume in each well was  
200  µl  and  the  plates were  incubated at  370 C, 5% CO2,  95%  air  and  100% 
relative  humidity for  48h.  The  medium  containing  without  samples  were  
served  as control. Triplicate was maintained for all concentrations.   
Procedure 
In-vitro anticancer screening 
  The human cervical cancer cell line (HeLa) was obtained from National 
Centre for Cell Science (NCCS), Pune. The cells were grown in Eagles Minimum 
Essential Medium containing 10% fetal bovine serum (FBS). 
For screening experiment, the cells were seeded into 96-well plates in 100µl of 
medium containing 5 %  FBS, at plating density of 10,000 cells/well and incubated 
at 37 
0
C, 5 % CO2, 95 % air and 100 % relative humidity for 24 hours prior to 
addition of samples. The samples were solubilized in Dimethyl sulfoxide and diluted 
in serum free medium. After 24 hours, 100 µl of the medium containing the samples 
at various concentration ( eg; 0.063, 0.125, 0.25, 0.5, 1.0 mM etc… ) was added and 
incubated at 370C, 5% CO2, 95% air and 100% relative humidity for 48 hours. 
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Triplicate was maintained and the medium containing without samples were served 
as control
41
. 
 After 48 hours, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) 
was added to each well and incubated at 37 0C for 4 hours. The medium with MTT 
was then flicked off and the formed formazan crystals were solubilized in 100µl of 
DMSO and then measured the absorbance at 570 nm using micro plate reader. The 
% cell inhibition was determined using the following formula.  
                       % cell Inhibition = 100 – {(sample) / Abs (control)} × 100 
Nonlinear  regression  graph  was  plotted  between  %  Cell  inhibition  and  Log10 
concentration and IC50 was determined using GraphPad Prism software.   
Statistical Analysis 
  All values are expressed as mean ± SEM. Data were analyzed by 
non-parametric ANOVA followed by Dunnett’s multiple comparison tests, and other 
data was evaluated using Graph Pad PRISM software. A p-value < 0.05 w 
as considered significantly different.    
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CHAPTER – 5 
RESULTS AND DISCUSSION 
5.1. Chemical work: 
  The results of the present work are discussed under the following heads. 
Scheme: 
  Synthesis of substituted N-(5-aryl-1, 3, 4-thiadiazole-2-yl)-2-alkyl / aryl 
substituted acetamides. 
 5.1.1. Synthesis of substituted N-(5-aryl-1, 3, 4-thiadiazole-2-yl)-2-alkyl / aryl 
substituted acetamides.  Synthetic route depicted in scheme outline the chemistry 
part of the present work. The N-(5-aryl-1, 3, 4-thiadiazole-2-yl)-2-alkyl / aryl 
substituted acetamides (TZ1-10) were obtained by the condensation of N-(5 aryl-1, 
3, 4-thiadiazole-2-yl)-2-chloroacetamide with alkyl and aryl substituted derivatives 
in presence of ethanol. The formation of the thiadiazole was confirmed by the 
presence of characteristic peaks in the IR spectra. It showed characteristic peaks at 
around 3400 cm
-1
 for NH2 stretching and peak around 2900 cm
-1 
due to the presence 
of  N=CH stretching. The NMR spectrum of the compounds TZ1-10 showed the 
characteristic peak around δ 2.70 ppm for CH3 group, δ 3.00 ppm for CH2 and δ 
5.70 ppm for NCH and also shows multiplet in the range of δ 6.80-7.80 ppm owing 
to aromatic protons. The appearance of peak due to chlorine, bromine and fluorine 
in IR spectra around 700 -800 cm-1 and formation M+2 peak in the mass spectra.  
Data from the elemental analyses and molecular ion recorded in the mass spectra 
further confirmed the assigned structure.  
5.2. Pharmacological Investigation 
         The anticancer screening of title compounds (TZ1-10) were evaluated against 
human cervical cancer cell line (HeLa) by MTT assay method. In  this assay  the 
effective  ranges of anticancer  activity  for compounds TZ1-10 were in the 
concentration of 0.1, 1.0, 10, 100 µM respectively in the  human  cervical  cancer  
cell line (HeLa).  Triplicate was maintained and the medium containing without 
samples were served as control. 
Results and discussion  
 
Dept.of Pharmaceutical Chemistry                 59            J.K.K.Nattraja College of Pharmacy 
 
         TZ1 (dimethylamino) produced IC50 value 45.70 µM in case of the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compounds TZ1 (dimethylamino) had  shown  the  
percentage  of  cell inhibition  was 74.85 against  the  human  cervical  cancer  cell  
line (HeLa) in  the highest concentration, which have dimethylamino group in the 
thiadiazole nucleus.    
        The  result  indicates  that TZ1 (dimethylamino group) showed  a  high   
significant  anticancer activity against  the human cervical cancer cell  line (HeLa), 
when compared  to that control.  
       TZ2 (pyrolidine) produced IC50 value 66.23 µM in case  of  the  human  
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compound TZ2 (pyrolidine) had  shown  the  
percentage  of  cell inhibition  was 52.89 against  the  human  cervical  cancer  cell  
line  (HeLa) in  the highest concentration, which have pyrolidine group in the 
thiadiazole nucleus. The results indicate that TZ2 (pyrolidine group) showed  a 
moderate anticancer activity against  the human cervical cancer cell  line (HeLa), 
when compared  to  that of control.  
      TZ3 (piperidine) produced IC50 value >100µM in  case  of  the  human  
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The compounds TZ2 (piperidine) had  shown  the 
percentage of cell inhibition was 51.30 against the human cervical cancer cell line 
(HeLa), which have piperidine group in the thiadiazole nucleus.    
 The results indicate that TZ3 (piperidine group) showed a less anticancer 
activity against  the human cervical cancer cell  line (HeLa), when compared  to  
that of control.  
 TZ4 (imidazole) produced  IC50 value 68.25 µM in case of  the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The compound TZ4 (imidazole)had  shown  the 
percentage of cell inhibition  was 62.85 against  the  human  cervical  cancer  cell  
line  (HeLa) in  the highest  concentration, which have  imidazole group in  the  
thiadiazole nucleus.  
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         The results indicate that TZ4 (imidazole group) showed a moderate 
significant anticancer activity against the human cervical cancer cell  line (HeLa), 
when compared  to  that of control. 
         TZ5 (morpholine) produced IC50 value 47.79 µM in  case  of  the  human  
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity.  The  compound S5  (Nitro) had  shown  the  
percentage  of  cell inhibition  was 70.89 against  the  human   cervical  cancer  cell  
line  (HeLa) in  the highest concentration, which have morpholine group in the 
thiadiazole nucleus.  
The  results  indicate  that TZ5 (morpholine group) showed  a good  
significant anticancer activity against  the human cervical cancer cell  line  (HeLa), 
when compared  to  that of control.  
TZ6 (dimethyl) produced  IC50 value 48.60 µM in  case  of  the  human  
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compound TZ6 (dimethyl) had  shown  the  
percentage  of  cell inhibition  was 73.85 against  the  human  cervical  cancer  cell  
line  (HeLa) in  the highest concentration, which have dimethyl group in the 
thiadiazole nucleus.  
The  results  indicate  that TZ6 (dimethylamino group) showed  a good  
significant anticancer activity against  the human cervical cancer cell  line  (HeLa), 
when compared  to  that of control. 
TZ7 (pyrolidine) produced IC50 value 75.26 µM in  case  of  the  human  
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compound TZ7 (dimethyl) had  shown  the  
percentage  of  cell inhibition  was 55.05 against  the  human  cervical  cancer  cell  
line  (HeLa) in  the highest concentration, which have dimethyl group in the 
thiadiazole nucleus.   
The  results  indicate  that TZ7 (pyrolidine group)  showed  a less  significant 
anticancer activity against  the human cervical cancer cell  line  (HeLa), when 
compared  to  that of control.  
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TZ8 (piperidine) produced IC50 value 92.36 µM in case of the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compound TZ8 (dimethyl) had  shown  the  
percentage  of  cell inhibition  was 60.82 against  the  human  cervical  cancer  cell  
line  (HeLa) in  the highest concentration, which have dimethyl group in the 
thiadiazole nucleus.    
The  results  indicate  that TZ8 (piperidine group)  showed  a less  significant 
anticancer activity against  the human cervical cancer cell  line  (HeLa), when 
compared  to  that of control.      
    TZ9 (imidazole) produced IC50 value 70.48 µM in case of the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compound TZ9 (dimethyl) had  shown  the  
percentage  of  cell inhibition  was 60.01against  the  human  cervical  cancer  cell  
line  (HeLa) in  the highest concentration, which have imidazole group in the 
thiadiazole nucleus.      
The  results  indicate  that TZ9 (imidazole group) showed  a less  significant 
anticancer activity against  the human cervical cancer cell  line  (HeLa), when 
compared  to  that of control.        
    TZ10 (morpholine) produced IC50 value 49.26 µM in case of the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample 
has more anticancer activity. The  compound TZ10 (morpholine) had  shown  the  
percentage  of  cell inhibition  was 70.12 against  the  human  cervical  cancer  cell  
line  (HeLa) in  the highest concentration, which have imidazole group in the 
thiadiazole nucleus.        
The  results  indicate  that TZ10 (morpholine group) showed  a less  
significant anticancer activity against  the human cervical cancer cell  line  (HeLa), 
when compared  to  that of control.           
The best mean IC50 values were achieved with compound (TZ1, TZ5, TZ6 
and TZ10) with slight difference among them.  
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Title compounds (TZ1-10) were found to exhibit mild to moderate anticancer 
activities in cell lines and the results were summarized below: 
 Compound TZ1 (dimethylamino) shows the high significant activity against 
the HeLa (IC50 – 47.50) cancer cell lines.  
 Compound TZ2 (pyrolidine) shows the significant activity against the HeLa 
(IC50 – 66.23) cancer cell lines. 
 Compound TZ3 (piperidine) shows the no action against the HeLa (IC50 > 
100) cancer cell lines.   
 Compound TZ4 (imidazole) shows the moderate significant against the HeLa 
(IC50 –67.668.25) cancer cell lines.  
 Compound TZ5 (morpholine) shows the high significant activity against the 
HeLa (IC50 – 47.79) cancer cell lines.  
 Compound TZ6 (dimethylamino) shows the moderate significant against the 
HeLa (IC50 –47.79) cancer cell lines.     
 Compound TZ7 (pyrolidine) shows the less significant against the HeLa 
(IC50 –75.26) cancer cell lines. 
 Compound TZ8 (piperidine) shows the less significant against the HeLa 
(IC50 –92.36) cancer cell lines. 
 Compound TZ9 (imidazole) shows the less significant against the HeLa 
(IC50 –70.48) cancer cell lines. 
 Compound TZ10 (morpholine) shows the significant activity against the 
HeLa (IC50 – 49.26) cancer cell lines. 
   Among the test compounds, compound 2-(dimethylamino)-N-(5-p-tolyl-
1,3,4-thiadiazol-2-yl)acetamide(TZ1) was found to be the most active agent which 
showed 74.85 percentage  of  cell inhibition against  the  human  cervical  cancer  
cell  line (HeLa) in  the highest concentration, which have dimethylamino group in 
the thiadiazole nucleus.   
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In vitro cytotoxicity studies on Human cervical cancer cell line (HeLa) 
 
 
PERCENTAGE OF CELL INHIBITION: 
 
 Table No. 2 
 
 
Compoun
ds 
Concentration % cell 
Inhibition 
Compound
s 
Concentration % cell 
Inhibition 
TZ1 0.1 µ M 1.3342 TZ6 0.1 µ M 1.2342 
1 µ M 12.6079 1 µ M 12.3079 
10 µ M 33.8761 10 µ M 32.9861 
100 µ M 74.8578 100 µ M 73.8578 
TZ2 0.1 µ M 1.0424 TZ7 0.1µ M 3.1895 
1 µ M 10.4447 1 µ M 14.2646 
10 µ M 22.9848 10 µ M 23.6772 
100 µ M 52.8995 100 µ M 55.0587 
TZ3 0.1 µ M 3.4112 TZ8 0.1µ M 1.4315 
1 µ M 13.7176 1 µ M 19.6317 
10 µ M 33.8976 10 µ M 35.4864 
100 µ M 51.3006 100 µ M 60.8275 
 0.1 µ M 1.5342 TZ9 0.1 µ M 1.4846 
 1 µ M 12.9079  1 µ M 11.3278 
TZ4 10 µ M 30.9861  10 µ M 30.3398 
 100 µ M 62.8578  100 µ M 60.0175 
 0.1 µ M 1.4424  0.1 µ M 1.4579 
TZ5 1 µ M 11.4447 TZ10 1 µ M 11.0145 
 10 µ M 28.9848  10 µ M 28.2358 
 100 µ M 70.8995  100 µ M 70.1268 
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Fig.No.5. Percentage Cell Inhibition on Human Cervical Cancer Cell Line (HeLa) 
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TZ 5  
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TZ 9  
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                                                                     TZ 10 
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           Table No.3: IC50 Values of Synthesized Compounds (TZ1 – TZ10) 
 
 
 
 
COMPOUND  CODE 
 
 
IC50 (MICRO MOLAR) 
TZ1 
45.70 µ M 
TZ2 
66.23 µ M 
TZ3 
>100 µ M 
TZ4 
68.25 µ M 
TZ5 
47.79 µ M 
TZ6 
48.60 µ M 
 
TZ7 
           
          75.26 µ M 
 
TZ8 
           
          92.36 µ M 
TZ9 
           
          70.48 µ M 
TZ10 
           
          49.26 µ M 
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Table No.4. TZ1 
 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 
1.3342 
 
 
 
45.70 
 
 
 
0.9995 
 
1 µM 
12.6079 
 
10 µM 
33.8761 
 
100 µM 
74.8578 
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Table No. 5. TZ2 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 
 
1.0424 
 
 
 
66.23 
 
 
 
0.9996 
 
1 µM 
 
10.447 
 
10 µM 
 
22.9848 
 
100 µM 
 
52.9885 
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Table No. 6. TZ3 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 3.4112 
 
 
 
>100 
 
 
 
0.9907 
 
1 µM 13.7176 
 
10 µM 33.8976 
 
100 µM 51.3006 
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Table No. 7. TZ4 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 1.5342 
 
 
 
68.25 
 
 
 
0.9367 
 
1 µM 12.9079 
 
10 µM 30.9861 
 
100 µM 62.8578 
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Table No. 8. TZ5 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 1.4424 
 
 
 
47.79 
 
 
 
0.9990 
 
1 µM 11.4447 
 
10 µM 28.9848 
 
100 µM 70.8995 
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Table No. 9. TZ6 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 1.2342 
 
 
 
48.60 
 
 
 
0.9916 
 
1 µM 12.3079 
 
10 µM 32.9861 
 
100 µM 73.8578 
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Table No. 10. TZ7 
 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 3.1895 
 
 
 
75.26 
 
 
 
0.9916 
 
1 µM 14.2646 
 
10 µM 23.6772 
 
100 µM 55.0587 
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Table No. 11. TZ8 
 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 1.4315 
 
 
 
92.36 
 
 
 
0.9916 
 
1 µM 19.6317 
 
10 µM 35.4864 
 
100 µM 60.8275 
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Table No. 12. TZ9 
 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 1.4846 
 
 
 
70.48 
 
 
 
0.9916 
 
1 µM 11.3278 
 
10 µM 30.3398 
 
100 µM 60.0175 
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Table No. 12. TZ10 
 
Concentration (µM) 
 
% Growth inhibition 
 
IC50 
 
R
2 
 
0.1 µM 1.4579 
 
 
 
49.26 
 
 
 
0.9916 
 
1 µM 11.0145 
 
10 µM 28.2358 
 
100 µM 70.1268 
 
 
 
     
 
 
 
 
 
 
                      
0
10
20
30
40
50
60
70
80
0 20 40 60 80 100 120
%
 C
e
ll
 G
r
o
w
t
h
 i
n
h
ib
it
io
n
Concentration (µM)
TZ10
Summary and Conclusion  
 
Dept.of Pharmaceutical Chemistry                          86            J.K.K.Nattraja College of Pharmacy 
 
 
CHAPTER – 6 
 
SUMMARY AND CONCLUSION  
 
  In summary, a new series of substituted N-(5-aryl-1, 3, 4-thiadiazole-2-yl)-2-
alkyl / aryl substituted acetamides were synthesized. These title compounds containing 
ten different substituents at C-2 and C-5 were screened for their anticancer agents. Most 
of the test compounds were found to exhibit significant anticancer activity against the 
human cervical cancer cell line (HeLa) in the highest concentration. Among the 
substituents at C-2, dimethyamino substituent and at C-5 4-methyl phenyl substitutent 
showed maximum potency, while morpholino and pyrolidine substitutent showed 
equipotent activity but the piperidine substituent at C-2 exhibited least activity when 
compare to other substituents. The order of activity at C-2 is dimethyamino ≥ 
morpholine ≥ imidazole ≥ pyrolidine ≥ piperidine group and at C-5 is 4-methyl ≥ 4-
bromo group.                   
        Among the test compounds, compound 2-(dimethylamino)-N-(5-p-tolyl-1,3,4-
thiadiazol-2-yl)acetamide (TZ1) was found to be the most active agent which showed 
74.85 percentage  of  cell inhibition against  the  human  cervical  cancer  cell  line 
(HeLa) in  the highest concentration, which have dimethylamino group in the 
thiadiazole nucleus.  
  Hence this molecule can be selected as a lead molecule of the present study for 
further exploitation.  
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CHAPTER - 7 
 
 
FUTURE PLAN OF WORK 
 
 
 
 
  It may conclude that further beneficial pharmacophore modifications in the 
design of novel 1, 3, 4-thiadiazole derivatives may be synthesized by designing novel 
ligands for therapeutic target by substituting different functional group and also 
examine with the help of NMR and X-ray which provide three dimensional frame 
works which can analyze structure activity data and can guide the design and 
synthesis of future potential therapeutic drugs towards other chronic disorders.  
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